Business Context and Reporting Period
This Form 8-K was filed by Aerpio Pharmaceuticals, Inc. on June 29, 2017. The report discloses a material event under Item 8.01 Other Events. Note: The request metadata references "Whitehawk Therapeutics, Inc.", but the filing text explicitly identifies the registrant as Aerpio Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical trial milestone and does not contain financial statements or quantitative financial data.
Material Changes
The primary material change reported is the initiation of patient dosing in the TIME-2b study on June 29, 2017. This Phase 2b clinical trial is designed to assess the efficacy and safety of the company's lead candidate, AKB-9778, for patients with moderate to severe non-proliferative diabetic retinopathy.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the clinical trial start. The filing incorporates a press release (Exhibit 99.1) by reference. No specific financial guidance, forward-looking projections, or detailed risk factors are enumerated within the text of this specific 8-K form.
Investor Verification Checklist
- Verify the correct registrant name (Aerpio Pharmaceuticals, Inc.) versus the metadata request (Whitehawk Therapeutics, Inc.).
- Review the attached press release (Exhibit 99.1) for detailed trial design and enrollment targets.
- Confirm the status of the AKB-9778 candidate in other ongoing or completed trials.
- Check subsequent filings for any updates on the TIME-2b study results or safety data.